ANDA 78484, held by Impax Labs. Galantamine Hydrobromide.
As of Nov 15, 2026, ANDA 78484 (Galantamine Hydrobromide), held by Impax Labs, was first approved by FDA on May 27, 2009, with 3 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 27, 2009 | Original application | Approved | None posted |
| Galantamine HydrobromideEQ 8MG BASE · capsule, extended release;oral | Galantamine Hydrobromide | Discontinued |
| Galantamine HydrobromideEQ 16MG BASE · capsule, extended release;oral | Galantamine Hydrobromide | Discontinued |
| Galantamine HydrobromideEQ 24MG BASE · capsule, extended release;oral | Galantamine Hydrobromide | Discontinued |
| Jun 28, 2023 | Supplement 10Labeling · Standard review | Approved | None posted |
| Jun 28, 2023 | Supplement 11Labeling · Standard review | Approved | None posted |
| Dec 6, 2019 | Supplement 8Labeling · Standard review | Approved | None posted |
| May 27, 2009 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters